Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Aclaris Therapeutics, retaining the price target of $16.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Aclaris Therapeutics’ promising pipeline and upcoming milestones. The company is on the verge of a transformative year in 2026, with several key developments expected to drive value. These include the advancement of bosakitug, an anti-TSLP monoclonal antibody, into a Phase 2 trial with results anticipated in the second half of 2026, and ATI-052, a bispecific monoclonal antibody, which is expected to complete its Phase 1 trials by the end of 2025 and early 2026. Additionally, ATI-2138 is set to enter Phase 2 trials for a new indication, and the company plans to initiate a next-generation ITK inhibitor program.
Aclaris Therapeutics’ ATI-052 stands out due to its potential best-in-class properties when compared to other clinical-stage monoclonal antibodies. The candidate has shown superior biologic activity, particularly in inhibiting CCL17 release, compared to several approved monoclonal antibodies. Furthermore, ATI-052 is engineered for enhanced half-life and reduced off-target binding, making it significantly more potent than existing combinations like dupilumab and tezepelumab. These advancements, along with the company’s strategic focus on developing next-generation bispecifics, underpin Selvaraju’s confidence in the stock’s potential, leading to the reiteration of a Buy rating and a 12-month price target of $16.
In another report released on October 15, Piper Sandler also maintained a Buy rating on the stock with a $6.00 price target.